Dr Reddy’s Laboratories Q1 Results FY26: Q1 PAT Jumps 1.85% to ₹1,418.10 crore; Revenue Surged 11.38% YoY
Posted by : sachet | Thu Jul 24 2025

Dr Reddy’s Laboratories Q1 Results FY26: Dr Reddy’s Laboratories posted its Q1 results on 23rd July 2025. The company posted robust numbers with Q1 PAT standing at ₹1,418.10 crores against a revenue of ₹8,572.10 crores. During Q1 FY26, the profit growth of the company was recorded at 1.85% YoY, and revenue gains for the same period were 11.38%.
Dr Reddy’s Laboratories Q1 Results 2025: Extracts of FY25 & FY26 (Consolidated Figures)
Particulars | Quarter Ended | |
30-06-2025 | 30-06-2024 | |
Revenue from Operations | ₹8,572.10 | ₹7,696.10 |
Profit Before Tax (PBT) | ₹2,463.90 | ₹2,317.10 |
Profit After Tax (PAT) | ₹1,418.10 | ₹1,392.40 |
(Figures in crore)
Dr Reddy’s Laboratories Q1 Results 2025: Extracts of FY25 & FY26 (Standalone Figures)
Particulars | Quarter Ended | |
30-06-2025 | 30-06-2024 | |
Revenue from Operations | ₹7,809.50 | ₹5,841.20 |
Profit Before Tax (PBT) | ₹4,235.30 | ₹2,170.80 |
Profit After Tax (PAT) | ₹2,961.20 | ₹1,417.20 |
(Figures in crore)
Dr Reddy’s Laboratories Q1 Results 2026 Highlights – (Q1 vs FY25)
- Dr Reddy’s Laboratories clocked Q1 FY26 consolidated revenue of ₹8,572.10 crores vs ₹7,696.10 crores.
- On the profit front, Dr Reddy’s Laboratories earned a consolidated PAT of ₹1,418.10 crore in Q1 FY26. During FY25, the company’s PAT stood at ₹1,392.40 crores.
- Consolidated PAT is up for the first quarter of FY26, was 1.85% YoY, and revenue gain was 11.38% YoY.
- As per the standalone figures, quarterly PAT of Dr Reddy’s Laboratories is up 108.95% and revenue has grown by 33.70% YoY.
Dr Reddy’s Laboratories Share Price Performance
On the opening bell of 24th July 2025, the shares of Dr Reddy’s Laboratories opened at ₹1,261.10.00 per share. However, the initial gains are sustained as of now, and Dr Reddy’s Laboratories shares are trading at ₹1,277.50 per share, higher than their opening price.
Considering the long-term performance, Dr Reddy’s Laboratories shares have yielded close to -6.34% returns in the past 1-year, and 5-year returns stand at 57.17%. Over the maximum timeframe, the Dr Reddy’s Laboratories share provided 25,150.99% returns to investors. However, one must ignore the risk of volatility in the stock market and invest in Dr Reddy’s Laboratories shares after thorough research.
For regular stock updates, dividend alerts, and expert verdicts, stay informed with Univest!
Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.
Also Read : Wipro Q1 Results FY26: Q1 PAT Soars 10.90 % to ₹3,330.40 crore; Revenue Rose 0.78% YoY
Recent Articles
Coforge Q1 Results FY26: Q1 PAT Jumps 138.29% to ₹317.40 crore; Revenue Surged 56.49% YoY
Bikaji Foods Q1 Results FY26: Q1 PAT Jumps 2.80% to ₹59.90 crore; Revenue Surged 14.18% YoY
Brigade Hotel Ventures IPO GMP: Day 1 IPO Live Updates
Force Motors Q1 Results FY26: Q1 PAT Jumps 52.40% to ₹176.33 crore; Revenue Surged 21.88% YoY
SRF Q1 Results FY26: Q1 PAT Jumps 71.41% to ₹432.32 crore; Revenue Surged 10.23% YoY
Infosys Q1 Results FY26: Q1 PAT Jumps 8.68% to ₹6,921.00 crore; Revenue Surged 7.54% YoY
Shanti Gold IPO GMP & Review: Apply or Avoid?
UBL Q1 Results FY26: Q1 PAT Jumps 5.95% to ₹183.87 crore; Revenue plunged 7.41% YoY
Related Posts
Regaal Resources IPO Allotment Status Check Online: GMP, Subscription, Price, and More
Ashok Leyland Q1 Results FY26: Q1 PAT Rises 12.97% to ₹593.73 Crore; Revenue Up 1.47% YoY
Brigade Enterprise Q1 Results FY26: Q1 PAT Soars 79.03% to ₹149.88 Crore; Revenue Up 18.88% YoY
KIOCL Q1 Results FY26: Q1 PAT Rises 25.49% to -₹37.79 Crore; Revenue Down 38.29% YoY
Anupam Rasayan Q1 Results FY26: Q1 PAT Rises 769.15% to ₹34.04 Crore; Revenue Up 91.12% YoY
